<DOC>
	<DOCNO>NCT01779479</DOCNO>
	<brief_summary>Cabazitaxel new taxoid promote tubulin assembly vitro stabilizes microtubule cold-induced depolymerization efficiently docetaxel select development base well antiproliferative activity resistant cell line docetaxel . It show superior survival mitoxantrone ( MTX ) plus prednisone docetaxel pre-treated hormone refractory metastatic prostate cancer patient lead registration compound . It show favorable toxicity profile interestingly low rate alopecia . In Genevieve study compare weekly paclitaxel currently widely use treatment breast cancer patient . A head-to-head comparison neoadjuvant set allow rapid precise comparison efficacy tolerability cabacitaxel versus paclitaxel decide far development taxoid breast cancer reasonable .</brief_summary>
	<brief_title>Efficacy Safety Cabazitaxel Versus Weekly Paclitaxel Neo-adjuvant Treatment Patients With Triple Negative Luminal B/HER2 Normal BC ( GENEVIEVE )</brief_title>
	<detailed_description>Primary Objective To compare pathologic complete response ( pCR ) rate breast ( ypT0/is ypN0/+ ) patient operable Triple Negative luminal B/HER2 normal breast cancer treat either cabazitaxel weekly paclitaxel . Secondary Objective To assess - pCR rate per arm separately stratify subpopulation . - Objective response rate ( ORR ) breast accord WHO criterion . - pCR rate define ypT0 ypN0 . - pCR rate define ypT0/is ypN0 . - pCR rate axillary lymph node ( ypN0 ) . - To determine pCR rate local recurrence free survival ( LRFS ) patient clinical complete response ( cCR ) negative core biopsy surgery . - Breast conservation surgery rate . - To assess toxicity ( NCI CTCAE V4.03 ) compliance arm . - Invasive loco-regional recurrence free survival ( LRRFS ) , distant-disease-free survival ( DDFS ) , invasive disease-free survival ( IDFS ) , overall survival ( OS ) . - To explore biomarkers profile potentially predict response treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>Written inform consent study accord local regulatory requirement prior begin specific protocol procedure . Complete baseline documentation must send GBG Forschungs GmbH . Unilateral bilateral primary carcinoma breast , confirm histologically core biopsy . Fineneedle aspiration alone sufficient . Incisional biopsy allow . In case bilateral cancer , investigator decide prospectively side evaluated primary endpoint . Tumor lesion breast palpable size &gt; = 2 cm sonographical size &gt; = 1 cm maximum diameter . The lesion measurable two dimension , preferably sonography . Patients must follow stage disease : cT3 cT2 cT1c cN+ cT1c pNSLN+ . In patient multifocal multicentric breast cancer , large lesion evaluate . Centrally confirm triple negative luminal B/HER2normal subtype . ER PgRnegative define &lt; 1 % stained cell . HER2 negative define IHC 0+ , 1+ IHC 2+ FISH/SISH/CISH ( ratio &lt; 2.0 ) negative . Luminal B define ER and/or PgR + &gt; 14 % Ki67 stain cell . The formalinfixed , paraffinembedded ( FFPE ) breast tissue block diagnostic core biopsy therefore send Dept . Pathology Charité , Berlin prior randomization . Age &gt; = 18 year . Eastern Cooperative Oncology Group ( ECOG ) Performance Status : 0 1 ( see Appendix A ) . Laboratory requirement : Hemoglobin &gt; 9.0 g/dL , Absolute neutrophil count &gt; 1.5 x 109/L , Platelet count &gt; 100 x 109/L , AST/SGOT and/or ALT/SGPT &lt; 2.5 x ULN ; Total bilirubin &lt; 1.0 x ULN , Serum creatinine &lt; 1.5 x ULN . If creatinine 1.0 1.5 x ULN , creatinine clearance calculate accord CKDEPI formula patient creatinine clearance &lt; 60 mL/min exclude ( see Appendix 2 formula ) . Negative pregnancy test ( urine serum ) within 14 day prior randomization woman childbearing potential . Complete stag workup within 3 month prior randomization . All patient must bilateral mammography , breast ultrasound ( &lt; = 21 day ) , breast MRI ( optional ) , chest Xray ( PA lateral ) , abdominal ultrasound CT scan MRI , bone scan do . In case positive bone scan , bone Xray mandatory . Other test may perform clinically indicate . Patients must available compliant central diagnostics , treatment followup . Any prior treatment primary breast cancer include radiation therapy History ipsi/ contralateral invasive breast cancer Locally advance disease include N3 metastatic disease Patients follow stage disease allow : cT4 Prior malignancy without diseasefree 5 year ( except carcinoma situ cervix situ cancer ( e.g . bladder cancer ) adequately treat basal cell carcinoma skin . Clinically significant ( i.e . active ) cardiovascular disease , include cerebrovascular accident ( ≤6 month enrolment ) , myocardial infarction , arterial thrombotic event ( ≤6 month enrolment ) , unstable angina pectoris , New York Heart Association ( NYHA ) ≥ grade 2 congestive heart failure and/or hypertension , serious cardiac arrhythmia require medication study might interfere regularity study treatment , control medication Any severe acute chronic medical condition could impair ability patient participate study comply study procedure interfere interpretation study result ( significant neurological psychiatric disorder include psychotic disorder , dementia seizure ) . Active infection . Sex hormone . Prior treatment must stop study entry . Inability unwillingness comply study visit , treatment , test , comply protocol . Administration live virus vaccine within 8 week precede study entry . Use investigational agent within 30 day administration first dose study drug concurrent treatment another clinical trial Requirement radiation therapy concurrent study anticancer treatment . Patients require breast chest wall radiation therapy surgery eligible Pregnancy breastfeed woman Patients childbearing potential agree use accept effective method contraception ( barrier method , intrauterine contraceptive device , sterilization ) study treatment period follow period 6 month last study drug administration . History hypersensitivity ( grade ≥ 3 ) polysorbate 80 study drug excipients Concurrent plan treatment potent strong inhibitor strong inducer cytochrome P450 3A4/5 ( twoweek washout period necessary patient already treatment ) ( see Appendix 3 ) Contraindications use corticosteroid treatment Symptomatic peripheral neuropathy grade ≥ 2 ( National Cancer Institute Common Terminology Criteria [ NCI CTCAE ] v.4.03 ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>German Breast Group</keyword>
	<keyword>GBG Forschungs GmbH</keyword>
	<keyword>GBG</keyword>
	<keyword>GBG 74</keyword>
	<keyword>Genevieve</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Primary Breast Cancer</keyword>
	<keyword>Cabazitaxel</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>neo-adjuvant</keyword>
	<keyword>triple negative</keyword>
	<keyword>luminal B</keyword>
</DOC>